News about "biotechnology company"

GSK to Acquire Chimagen's Trispecific T-Cell Engager for Multiple Myeloma

GSK agrees to acquire global rights to Chimagen Biosciences’ investigational trispecific T-cell engager for multiple myeloma in a deal valued at up to USD 750 million.

Biotechnology Company | 16/09/2026 | By News Bureau

Mediar Therapeutics, Ono Pharma Enter Collaboration to Develop Novel Fibrosis Therapies

Mediar Therapeutics and Ono Pharmaceutical have entered a collaboration and option agreement to discover novel therapies targeting fibro-inflammatory diseases, while Mediar advances its pipeline of fibrosis-focused antibody programmes.

Biotechnology Company | 10/08/2026 | By News Bureau |  117

Aspen Neuroscience's Parkinson's Cell Therapy Receives US FDA RMAT Designation

Aspen Neuroscience has received US FDA Regenerative Medicine Advanced Therapy designation for sasineprocel (ANPD001), its investigational autologous cell therapy for Parkinson's disease.

Biotechnology Company | 31/07/2026 | By News Bureau |  141

Healx Doses First Patient in Phase 1/2 Trial of AI-Discovered Therapy for Relapsed Osteosarcoma

Healx has dosed the first patient in its Phase 1/2 trial of AI-developed investigational therapy HLX-4310, marking a milestone in the development of novel treatments aimed at preventing metastatic recurrence in osteosarcoma and other rare cancers.

Biotechnology Company | 24/07/2026 | By News Bureau |  154

Insilico Medicine, Bora Pharmaceuticals Forge Alliance to Advance AI-Driven Drug Discovery and Manufacturing

The collaboration between Insilico Medicine and Bora Pharmaceuticals is valued at over USD 2.5 billion if fully implemented and aims to accelerate the discovery, development and commercialisation of next-generation therapies while expanding AI adoption across the pharmaceutical value chain.

Biotechnology Company | 16/07/2026 | By News Bureau |  153

AtaiBeckley Completes Patient Dosing in Phase 2b Trial of VLS-01 for Treatment-Resistant Depression

AtaiBeckley has completed dosing the final patient in its Phase 2b Elumina trial evaluating VLS-01 for treatment-resistant depression. The company expects topline results in the fourth quarter of 2026 and plans to expand the therapy into major depressive disorder and generalized anxiety disorder, subject to positive clinical outcomes.

Biotechnology Company | 07/07/2026 | By News Bureau |  129

Armata Pharmaceuticals Receives FDA Fast Track Designation for AP-SA02 Bacteriophage Therapy

The FDA has granted Fast Track designation to Armata’s AP-SA02 therapy for the adjunct treatment of complicated Staphylococcus aureus bacteremia caused by MSSA and MRSA infections.

Biotechnology Company | 07/05/2026 | By News Bureau |  199

Cbio A/S Secures Regulatory Clearance for First-in-Human Trial of Novoleucel T-Cell Therapy for Cervical Cancer

Cbio A/S has received regulatory approval to begin a Phase I/IIa trial of novoleucel, a next-generation T-cell therapy, in patients with recurrent Cervical Cancer.

Biotechnology Company | 16/03/2026 | By News Bureau |  249

Immunic Secures European Patent for Vidofludimus Calcium, Strengthening Long-Term Market Exclusivity

Immunic receives European patent protection for Vidofludimus Calcium dosing regimens, reinforcing intellectual property coverage and potentially extending exclusivity for the multiple sclerosis therapy in Europe until 2043.

Biotechnology Company | 12/03/2026 | By News Bureau |  147

Antengene Licenses ATG-201 to UCB in Deal Worth Up to USD 1.1 Billion for Autoimmune Disease Therapy

Antengene grants UCB exclusive global rights to develop and commercialise ATG-201, a CD19/CD3 bispecific T-cell engager targeting autoimmune diseases, in a deal worth over USD 1.1 billion in milestones and royalties.

Biotechnology Company | 06/03/2026 | By News Bureau |  261